Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 14; no. 2; pp. 155 - 162.e1
• Main Authors: Ohanian, Maro, Kantarjian, Hagop M, Quintas-Cardama, Alfonso, Jabbour, Elias, Abruzzo, Lynne, Verstovsek, Srdan, Borthakur, Gautam, Ravandi, Farhad, Garcia-Manero, Guillermo, Champlin, Richard, Pierce, Sherry, Alattar, Mona Lisa, Trinh, Long Xuan, Luthra, Raja, Ferrajoli, Alessandra, Kadia, Tapan, O'Brien, Susan, Cortes, Jorge E
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2014
• Subjects: Accelerated phase CML (CML-AP); Adult; Aged; Aged, 80 and over; Benzamides - therapeutic use; Complete cytogenetic response (CCyR); Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Hematology, Oncology and Palliative Medicine; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase - diagnosis; Leukemia, Myeloid, Accelerated Phase - drug therapy; Leukemia, Myeloid, Accelerated Phase - genetics; Major molecular response (MMR); Male; Middle Aged; Piperazines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Pyrimidines - therapeutic use; Second generation TKI (2GTKIs); Thiazoles - therapeutic use; Time Factors; Treatment Outcome; Tyrosine kinase inhibitors (TKI); Young Adult; Complete cytogenetic response (CCyR); Major molecular response (MMR); Second generation TKI (2GTKIs); Tyrosine kinase inhibitors (TKI); Accelerated phase CML (CML-AP)
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2013.08.008

Micro-Abstract Some patients with chronic myeloid leukemia (CML) present with accelerated phase (AP) features at the time of diagnosis. We analyzed the outcome of 51 consecutive patients with de novo CML-AP who received tyrosine kinase inhibitors (TKIs) as initial therapy. Patients with de novo CML-AP have excellent outcomes with TKIs as initial therapy, particularly with second-generation TKIs (2GTKI).